KC
PTCT icon

Kepos Capital’s PTC Therapeutics PTCT Stock Holding History

Kepos Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-32,294
Closed -$1.22M – 394
2019
Q1 		$1.22M Hold
32,294
– – 0.09% 198
2018
Q4 		$1.11M Hold
32,294
– – 0.09% 206
2018
Q3 		$1.52M Hold
32,294
– – 0.08% 191
2018
Q2 		$1.09M Buy
+32,294
New +$1.01M 0.06% 215

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Kepos Capital's PTCT Position: Q2 2019 in Review

Kepos Capital sold out of PTC Therapeutics (PTCT) in Q2 2019, closing a stake of 32,294 shares — an estimated $1.22M sold.

Kepos Capital first reported a position in PTCT in Q2 2018 and held it in 4 quarters. The position peaked at $1.52M in Q3 2018. 176 funds tracked by Wall St. Rank hold PTCT as of Q2 2019.

  • Kepos Capital reported no remaining PTC Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Kepos Capital sold 32,294 PTC Therapeutics shares in Q2 2019, an estimated $1.22M.
  • Kepos Capital first reported a position in PTC Therapeutics in Q2 2018 and held it in 4 quarters.
  • Kepos Capital's PTC Therapeutics position peaked at $1.52M in Q3 2018.
  • 176 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2019.

Based on Kepos Capital's 13F filing for Q2 2019, filed 13 Aug 2019.